BP-897

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 386255446

| IUPAC_name = N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide

| image = BP-897 Structure.svg

| tradename =

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| IUPHAR_ligand = 7625

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 314776-92-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 20PLE5W821

| ATC_prefix = none

| ATC_suffix =

| PubChem = 3038495

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 25236

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 2302059

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| StdInChI = 1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = MNHDKMDLOJSCGN-UHFFFAOYSA-N

| C=26 | H=31 | N=3 | O=2

| smiles = COc1ccccc1N3CCN(CC3)CCCCNC(=O)c4ccc2ccccc2c4

}}

BP-897 is a drug used in scientific research which acts as a potent selective dopamine D₃ receptor partial agonist with an in vitro intrinsic activity of ~0.6 and ~70x greater affinity for D₃ over D₂ receptors and is suspected to have partial agonist or antagonist activity in vivo.{{cite journal | vauthors = Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P | display-authors = 6 | title = Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist | journal = Nature | volume = 400 | issue = 6742 | pages = 371–375 | date = July 1999 | pmid = 10432116 | doi = 10.1038/22560 | s2cid = 4351316 }} It has mainly been used in the study of treatments for cocaine addiction.{{cite journal | vauthors = Beardsley PM, Sokoloff P, Balster RL, Schwartz JC | title = The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered | journal = Behavioural Pharmacology | volume = 12 | issue = 1 | pages = 1–11 | date = February 2001 | pmid = 11270507 | doi = 10.1097/00008877-200102000-00001 | s2cid = 25443354 | doi-access = free }}{{cite journal | vauthors = Garcia-Ladona FJ, Cox BF | title = BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction | journal = CNS Drug Reviews | volume = 9 | issue = 2 | pages = 141–158 | year = 2003 | pmid = 12847556 | pmc = 6741652 | doi = 10.1111/j.1527-3458.2003.tb00246.x }}{{cite journal | vauthors = Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiébot MH | title = Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats | journal = Neuropsychopharmacology | volume = 28 | issue = 11 | pages = 1903–1915 | date = November 2003 | pmid = 12915863 | doi = 10.1038/sj.npp.1300276 | doi-access = free }}{{cite journal | vauthors = Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M | title = Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 311 | issue = 2 | pages = 770–777 | date = November 2004 | pmid = 15226382 | doi = 10.1124/jpet.104.071142 | s2cid = 15481124 }}{{cite journal | vauthors = Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX | display-authors = 6 | title = Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors | journal = Synapse | volume = 57 | issue = 1 | pages = 17–28 | date = July 2005 | pmid = 15858839 | pmc = 3726034 | doi = 10.1002/syn.20152 }}{{cite journal | vauthors = Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Gaál J, Gardner EL | display-authors = 6 | title = The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats | journal = Psychopharmacology | volume = 196 | issue = 4 | pages = 533–542 | date = March 2008 | pmid = 17985117 | pmc = 3713235 | doi = 10.1007/s00213-007-0986-6 }}{{cite journal | vauthors = Hocke C, Prante O, Salama I, Hübner H, Löber S, Kuwert T, Gmeiner P | title = 18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor | journal = ChemMedChem | volume = 3 | issue = 5 | pages = 788–793 | date = May 2008 | pmid = 18306190 | doi = 10.1002/cmdc.200700327 | s2cid = 23143152 }} A study comparing BP-897 with the potent, antagonistic, and highly D₃ selective SB-277,011-A found, "SB 277011-A (1–10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."{{cite journal | vauthors = Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaál J, Le Foll B | display-authors = 6 | title = The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking | journal = The International Journal of Neuropsychopharmacology | volume = 13 | issue = 2 | pages = 181–190 | date = March 2010 | pmid = 19995481 | doi = 10.1017/S1461145709991064 | doi-access = free }}